Catalogo dei prodotti della ricerca

STEFANIZZI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.560
EU - Europa 390
AS - Asia 113
SA - Sud America 13
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.086
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.555
IT - Italia 102
UA - Ucraina 102
SE - Svezia 75
IN - India 55
CN - Cina 34
FI - Finlandia 33
GB - Regno Unito 27
BG - Bulgaria 22
SG - Singapore 19
AR - Argentina 11
BE - Belgio 11
DE - Germania 7
TG - Togo 5
HK - Hong Kong 4
CA - Canada 3
RU - Federazione Russa 3
CL - Cile 2
IE - Irlanda 2
MX - Messico 2
RO - Romania 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
CH - Svizzera 1
EU - Europa 1
IL - Israele 1
MK - Macedonia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
Totale 2.086
Salva come PNG Salva come JPEG
Città #
Fairfield 278
Houston 161
Woodbridge 140
Ann Arbor 119
Chandler 119
Ashburn 95
Seattle 89
Cambridge 80
Wilmington 74
San Paolo di Civitate 44
Jacksonville 37
Princeton 32
Plano 31
Rome 28
Beijing 27
Lawrence 27
Millbury 22
Sofia 22
Des Moines 18
Bologna 14
San Diego 14
Boston 12
Trento 12
Brussels 11
Federal 11
Boardman 10
Singapore 10
Andover 9
Dearborn 5
Lomé 5
Hong Kong 4
Norwalk 4
Los Angeles 3
San Mateo 3
Bremen 2
Dublin 2
Falls Church 2
Fremont 2
Hefei 2
London 2
San Francisco 2
Simi Valley 2
Southend 2
Toronto 2
Washington 2
Acton 1
Auburn Hills 1
Auckland 1
Bern 1
Buffalo 1
Bühl 1
Changsha 1
Guadalajara 1
Lappeenranta 1
Mexico City 1
Modderfontein 1
Monsano 1
Muizenberg 1
Nanchang 1
New Albany 1
New York 1
Ohrid 1
Ottawa 1
Philadelphia 1
Providence 1
Redwood City 1
Tappahannock 1
Treviso 1
Trumbull 1
Turin 1
Visoko 1
Yinchuan 1
Totale 1.619
Salva come PNG Salva come JPEG
Nome #
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease 115
WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients? 100
Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature 95
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy 93
Pregnancy in patients with myelodysplastic syndromes (MDS) 89
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems 89
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance 86
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? 84
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal 82
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: AN IMMUNOMODULATORY EFFECT? 81
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study 79
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. 77
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib 75
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia 73
Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient 69
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib 67
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience 64
Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients 63
Ara-C, idarubicine and Gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients 62
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia 59
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. 59
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. 58
Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. 56
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. 56
Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection. 55
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results 51
Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications. 47
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma. 35
ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN VERY ELDERLY PATIENTS (> 70 YEARS) 30
Biologic and clinical significance of CD34 expression in acute promyelocytic leukemia 29
Phenotypic and molecular features of acute promyelocytic leukemia patients developing retinoic acid syndrome 25
Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia 14
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas 8
Totale 2.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019194 0 0 0 0 0 0 0 0 0 0 109 85
2019/2020534 73 25 10 33 53 65 60 70 58 47 29 11
2020/2021160 32 27 7 11 7 13 5 16 10 18 9 5
2021/2022354 3 30 42 6 38 9 9 41 25 27 59 65
2022/2023431 57 97 28 39 50 94 4 15 29 3 10 5
2023/2024108 9 21 3 6 6 25 2 3 4 20 9 0
Totale 2.125